<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745091</url>
  </required_header>
  <id_info>
    <org_study_id>0201372</org_study_id>
    <nct_id>NCT04745091</nct_id>
  </id_info>
  <brief_title>MRI Split Scar Sign as a Predictor to Complete Pathologic Response After Neoadjuvant Chemoradiation in Rectal Cancer</brief_title>
  <official_title>Complete Clinical Response With MRI Split Scar Sign as a Predictor to Complete Pathologic Response After Neoadjuvant Chemoradiation in Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with middle or low rectal cancer who receive neoadjuvant chemoradiation and achieve&#xD;
      complete clinical response while their pelvic MRI have split scar sign are included. Patients&#xD;
      will have total mesorectal excision and pathologic complete response will be assessed&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with middle or low rectal cancer who have T3-4 and/ or N+ will be included. Patients&#xD;
      will receive neoadjuvant chemoradiation in the form of pelvic irradiation by 50.4 thousands&#xD;
      grays together with radio sensitization by 5-FU or oxaliplatin, 8 months after completion of&#xD;
      neoadjuvant chemoradiation patients will be assessed clinically and radiologically. Complete&#xD;
      clinical response is diagnosed if clinically no tumor is felt or just small scar and no tumor&#xD;
      appears in MRI. Of these patients who achieve complete clinical response we will pick up&#xD;
      cases who have split scar sign in the pelvic MRI. Patients will have total mesorectal&#xD;
      excision 8-11 weeks after completion of neoadjuvant chemoradiation and pathologic complete&#xD;
      response will be assessed. Correlation will be done between preoperative clinical response&#xD;
      and postoperative pathologic response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete pathologic response</measure>
    <time_frame>after surgical excision with follow up of an average of 1 year</time_frame>
    <description>disappearance of tumor from resected specimen</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rectum Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>total mesorectal excision</intervention_name>
    <description>excision of the rectum with complete excision of the mesorectum</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      rectal cancer specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        locally advance middle and low rectal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        middle and low rectal cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khaled Madbouly, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alexandria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khaled Madbouly, MD, PhD</last_name>
    <phone>+2034802375</phone>
    <email>khaled.madbouly@alexmed.edu.eg</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 30, 2021</study_first_submitted>
  <study_first_submitted_qc>February 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 6, 2021</last_update_submitted>
  <last_update_submitted_qc>February 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Khaled Madbouly</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>no approval yet from ethical committee to share data. Not written in patients' consent yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

